What is the official website of Baxter Deutschland, Österreich, Schweiz ?

The official website of Baxter Deutschland, Österreich, Schweiz is https://www.baxter.de/de.

What is Baxter Deutschland, Österreich, Schweiz's cybersecurity risk score?

Baxter Deutschland, Österreich, Schweiz has an AI-generated cybersecurity risk score of 754 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Baxter Deutschland, Österreich, Schweiz experienced?

According to Rankiteo, Baxter Deutschland, Österreich, Schweiz currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Baxter Deutschland, Österreich, Schweiz been affected by any supply chain cyber incidents ?

According to Rankiteo, Baxter Deutschland, Österreich, Schweiz has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Baxter Deutschland, Österreich, Schweiz have SOC 2 Type 1 certification ?

According to Rankiteo, Baxter Deutschland, Österreich, Schweiz is not certified under SOC 2 Type 1.

Does Baxter Deutschland, Österreich, Schweiz have SOC 2 Type 2 certification ?

According to Rankiteo, Baxter Deutschland, Österreich, Schweiz does not hold a SOC 2 Type 2 certification.

Does Baxter Deutschland, Österreich, Schweiz comply with GDPR ?

According to Rankiteo, Baxter Deutschland, Österreich, Schweiz is not listed as GDPR compliant.

Does Baxter Deutschland, Österreich, Schweiz have PCI DSS certification ?

According to Rankiteo, Baxter Deutschland, Österreich, Schweiz does not currently maintain PCI DSS compliance.

Does Baxter Deutschland, Österreich, Schweiz comply with HIPAA ?

According to Rankiteo, Baxter Deutschland, Österreich, Schweiz is not compliant with HIPAA regulations.

Does Baxter Deutschland, Österreich, Schweiz have ISO 27001 certification ?

According to Rankiteo,Baxter Deutschland, Österreich, Schweiz is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Baxter Deutschland, Österreich, Schweiz operate in ?

Baxter Deutschland, Österreich, Schweiz operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Baxter Deutschland, Österreich, Schweiz have ?

Baxter Deutschland, Österreich, Schweiz employs approximately None employees people worldwide.

Does Baxter Deutschland, Österreich, Schweiz own any subsidiaries ?

Baxter Deutschland, Österreich, Schweiz presently has no subsidiaries across any sectors.

How many LinkedIn followers does Baxter Deutschland, Österreich, Schweiz have ?

Baxter Deutschland, Österreich, Schweiz's official LinkedIn profile has approximately 2,480 followers.

What is the NAICS classification code for Baxter Deutschland, Österreich, Schweiz ?

Baxter Deutschland, Österreich, Schweiz is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Baxter Deutschland, Österreich, Schweiz have a Crunchbase profile ?

No, Baxter Deutschland, Österreich, Schweiz does not have a profile on Crunchbase.

Does Baxter Deutschland, Österreich, Schweiz have a LinkedIn profile ?

Yes, Baxter Deutschland, Österreich, Schweiz maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/baxter-dach.

How many cybersecurity incidents has Baxter Deutschland, Österreich, Schweiz experienced ?

As of August 29, 2026, Rankiteo reports that Baxter Deutschland, Österreich, Schweiz has experienced 3 cybersecurity incidents.

How many peer or competitor companies does Baxter Deutschland, Österreich, Schweiz have ?

Baxter Deutschland, Österreich, Schweiz has an estimated 5,746 peer or competitor companies worldwide.

What types of cybersecurity incidents has Baxter Deutschland, Österreich, Schweiz faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

BDÖS

Boost Score +25 with badge (5 left)

754

/1000

Fair

779

/1000

Fair

Baxter Deutschland, Österreich, Schweiz Vendor Cyber Rating & Cyber Score

baxter.de

Add Your Compliance Badge

Unsere Produkte und Therapien werden täglich von Millionen Menschen weltweit angewendet. Sie sind überall dort im Einsatz, wo Leben gerettet und wieder lebenswert gemacht werden: in Krankenhäusern, Arztpraxen und bei den Menschen zu Hause. Patienten und Ärzte vertrauen auf unsere lebensrettenden Produkte aus den Bereichen Nierenersatztherapie, Anästhesie, Chirurgie, künstliche Ernährung, Onkologie und Schmerztherapie. Baxters Mission Leben zu retten und zu erhalten motiviert und verbindet weltweit rund 50.000 Mitarbeitende in über 100 Ländern. Baxter ist in Deutschland, Österreich und der Schweiz seit langem präsent und engagiert. In den drei Ländern arbeiten rund 2.500 Beschäftigte in 11 Standorten. Wir begrüßen alle Hillrom Mitarbeiter

BDÖS A.I CyberSecurity Scoring

Scoring History

BDÖS

Baxter Deutschland, Österreich, Schweiz CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Baxter Internationa...

Breach

8/2026

HIMBAX178776435...

Baxter Deutschland,...

Breach

6/2024

BAX326072825

Baxter Deutschland,...

Breach

5/2024

BAX012072925

Loading…

A.I.

BDÖS Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for BDÖS

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Baxter Deutschland, Österreich, Schweiz in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Baxter Deutschland, Österreich, Schweiz in 2026.

Incident Types BDÖS vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Baxter Deutschland, Österreich, Schweiz in 2026.

Incident History - BDÖS (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Baxter Deutschland, Österreich, Schweiz Subsidiaries

BDÖS

Pharmaceutical Manufacturing

Website: https://www.baxter.de/de

Company Size: 1,001-5,000 employees

Baxter International Inc.Medical Equipment Manufacturing

Renal Care ServicesFabricación de equipo médico

Baxter ColombiaFabricación de equipo médico

Baxter Australia and New ZealandHospitals and Health Care

Baxter BrasilFabricação de instrumentos e materiais para uso médico e odontológico e de artigos ópticos

Baxter Healthcare India Medical Equipment Manufacturing

Loading…

Baxter Deutschland, Österreich, Schweiz Similar Companies

Hikma Pharmaceuticals

cb hikma.com

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

Parexel

parexel.com

Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.

MANKIND PHARMA LTD

mankindpharma.com

Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries and CIS countries. Our Vision - To be a global pharmaceutical company, most admired for its Affordability, Quality and Accessibility of products. Our Mission - To be able to provide cost-effective, innovation based superior quality pharmaceutical products across the globe, to improve the lives of the patients. Mankind strongly believes and follows its Core Values: 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐂𝐞𝐧𝐭𝐫𝐢𝐜𝐢𝐭𝐲: Commitment to Customer - Internal and External 𝐐𝐮𝐚𝐥𝐢𝐭𝐲: It is in our DNA to maintain and deliver highest quality standards and products 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Intensely Research driven organization aiming at product innovation and technology improvements 𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲: Always trustworthy, widely respected to be honest, and believed by everyone 𝐆𝐨 𝐁𝐞𝐲𝐨𝐧𝐝: Aim higher than capabilities 𝐏𝐞𝐨𝐩𝐥𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Together we are foreseeing future and diligently stimulating our people in attaining goals

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

AUROBINDO PHARMA LTD

aurobindo.com

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

Ipca Laboratories Limited

ipca.com

A consumer-led global pharmaceutical company, creating healthy doses of life since 1949. When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need for utmost integriti in everything you do. As you serve millions of lives, high qualiti standards become a pre-requisite, and safeti of your people and consumers always comes first. All this, while ensuring that each life you touch is treated with respect and digniti. For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others. - One of the largest suppliers of these APIs worldwide with manufacturing leadership in over 12 APIs globally - 15 APIs & 11 Formulations manufacturing facility across the globe Leader in DMARDs (Disease Modifying Anti-Rheumatic Drugs) treatment for Rheumatoid Arthritis - Leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy - 4 formulations rank amongst the top 300 brands of IPM as per IQVIA

Viatris

viatris.com

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

Loading…

NEWS

Baxter Deutschland, Österreich, Schweiz CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-55867

SUMMARY

Graylog is a free and open log management platform. From 6.2.0 until 6.3.12, 7.0.7, and 7.1.2, the DELETE /users/{userId}/tokens/{idOrToken} endpoint implemented by UsersResource.revokeToken() in graylog2-server/src/main/java/org/graylog2/rest/resources/users/UsersResource.java checks USERS_TOKENREMOVE permission against the attacker-controlled userId path parameter before resolving the token selected by idOrToken. An authenticated user can provide an authorized userId while accessTokenService.loadById() or accessTokenService.load() resolves a token belonging to another user, including a service account or administrator, after which accessTokenService.destroy() deletes that token without checking AccessToken.getUserName(). The issue does not expose token contents, but unauthorized deletion causes integrity impact and can disrupt access-token-based integrations. This issue is fixed in versions 6.3.12, 7.0.7, and 7.1.2.

Published

Date2026-08-28

Updated

Date2026-08-28

RISK INFORMATION (Score: )

cvss4

Base Score: 5.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:N/VI:L/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-55860

SUMMARY

MariaDB Connector/R2DBC is a non-blocking MariaDB and MySQL client implemented in Java. Prior to 1.4.1, org.mariadb:r2dbc-mariadb does not gate clear-text password authentication plugins on transport encryption because the AuthenticationPlugin interface has no capability for a plugin to require a secure connection. A hostile or man-in-the-middle MariaDB server can send an AuthSwitchRequest naming mysql_clear_password or dialog (PAM) over a plain-TCP unencrypted connection, and AuthenticationFlow permits ClearPasswordPluginFlow or PamPluginFlow to return the user's password as cleartext bytes on the wire. The disclosed credentials can subsequently be used to authenticate directly to the database server. This issue is fixed in version 1.4.1.

Published

Date2026-08-28

Updated

Date2026-08-28

RISK INFORMATION (Score: 5.9)

cvss3

Base Score: 5.9

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:H/I:N/A:N

Impact Score

3.6

Exploitability

2.2

REFERENCES

CVE-2026-55859

SUMMARY

MariaDB Connector/R2DBC is a non-blocking MariaDB and MySQL client implemented in Java. Prior to 1.4.1, org.mariadb:r2dbc-mariadb encodes and decodes all character data under the assumption that the connection character set is UTF-8. A server can announce a mid-session change to character_set_client through the OK-packet session-state-tracking mechanism, including through SET NAMES executed by a stored routine or trigger, server configuration, or a hostile or man-in-the-middle server. If the new character set is not UTF-8, the driver continues to exchange UTF-8 while the server interprets the same bytes under a different encoding, causing silent data corruption and a client/server charset-confusion mismatch that can defeat byte-wise quoting or escaping. The fix accepts only utf8, utf8mb3, or utf8mb4 after initialization; any other value raises R2dbcNonTransientResourceException with SQLState 08000 and closes the connection. This issue is fixed in version 1.4.1.

Published

Date2026-08-28

Updated

Date2026-08-28

RISK INFORMATION (Score: 5.9)

cvss3

Base Score: 5.9

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:N/I:H/A:N

Impact Score

3.6

Exploitability

2.2

REFERENCES

CVE-2026-55858

SUMMARY

MariaDB Connector/J is used to connect applications developed in Java to MariaDB and MySQL databases. Prior to 2.7.14, 3.3.5, 3.4.3, and 3.5.9, the connector encodes and decodes protocol text and performs client-side escaping under the assumption that the connection character set is UTF-8. The server can report a mid-session change to character_set_client through OK-packet session-state tracking, including a change caused by SET NAMES, a stored routine or trigger, server configuration, or a hostile server. If character_set_client changes to a non-UTF-8 value, the driver continues to read and write UTF-8 while the server interprets the same bytes under another encoding, causing silent data corruption and a client/server charset-confusion mismatch that can defeat byte-wise quoting or escaping. The fix accepts only utf8, utf8mb3, or utf8mb4 after initialization; any other value causes SQLException with SQLState 08000 and closes the connection. This issue is fixed in versions 2.7.14, 3.3.5, 3.4.3, and 3.5.9.

Published

Date2026-08-28

Updated

Date2026-08-28

RISK INFORMATION (Score: 5.9)

cvss3

Base Score: 5.9

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:N/I:H/A:N

Impact Score

3.6

Exploitability

2.2

REFERENCES

CVE-2026-55857

SUMMARY

MariaDB Connector/J is used to connect applications developed in Java to MariaDB and MySQL databases. Prior to 2.7.14, 3.3.5, 3.4.3, and 3.5.9, PAM dialog authentication can be coerced into transmitting the account password over an insecure connection. The mysql_clear_password plugin is gated behind a secure transport, but the sibling PAM handler SendPamAuthPacketFactory, named dialog by the server, does not declare that requirement and inherits the default secure-required value false; older branches implement the same affected behavior in SendPamAuthPacket. A hostile or man-in-the-middle server can send an Authentication Switch Request for dialog over plain TCP, causing the driver to return the user's password in cleartext when sslMode=DISABLE and restrictedAuth=null, which is the default configuration. Properly verified TLS and local Unix sockets are not exposed to this transport vector. This issue is fixed in versions 2.7.14, 3.3.5, 3.4.3, and 3.5.9.

Published

Date2026-08-28

Updated

Date2026-08-28

RISK INFORMATION (Score: 5.9)

cvss3

Base Score: 5.9

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:H/I:N/A:N

Impact Score

3.6

Exploitability

2.2

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…